Dosing of cd38-binding fusion protein

A method of treating melanoma, the method comprising administering to a subject in need thereof a composition comprising 60-120 mg of a CD38-binding fusion protein, wherein the CD38-binding fusion protein comprises an anti-CD38 antibody fused to an attenuated interferon alpha-2b.

A method of treating melanoma, the method comprising administering to a subject in need thereof a composition comprising a CD38-binding fusion protein, wherein the CD38-binding fusion protein comprises an anti-CD38 antibody fused to an attenuated interferon alpha-2b, wherein the CD38-binding fusion protein is administered at 0.1-1.5 mg/kg of the subject once every three weeks, and wherein the subject is receiving or has received treatment with an immune checkpoint inhibitor.

A method of treating melanoma, the method comprising administering to a subject in need thereof a composition comprising an immune checkpoint inhibitor, wherein the subject is receiving or has received treatment with a CD38-binding fusion protein, wherein the CD38-binding fusion protein comprises an anti-CD38 antibody fused to an attenuated interferon alpha-2b, wherein the CD38-binding fusion protein is administered at 0.1-1.5 mg/kg of the subject once every three weeks.

A method of treating melanoma, the method comprising administering to a subject in need thereof a composition comprising a CD38-binding fusion protein, wherein the CD38-binding fusion protein comprises an anti-CD38 antibody fused to an attenuated interferon alpha-2b, wherein 60-120 mg of the CD38-binding fusion protein is administered once every three weeks, and wherein the subject is receiving or has received treatment with an immune checkpoint inhibitor.

A method of treating melanoma, the method comprising administering to a subject in need thereof a composition comprising an immune checkpoint inhibitor, wherein the subject is receiving or has received treatment with a CD38-binding fusion protein, wherein the CD38-binding fusion protein comprises an anti-CD38 antibody fused to an attenuated interferon alpha-2b, wherein 60-120 mg of the CD38-binding fusion protein is administered once every three weeks.

A CD38-binding fusion protein for use in a method of treating melanoma, the method comprising administering to a subject in need thereof the CD38-binding fusion protein at 0.1-1.5 mg/kg of the subject once every three weeks, wherein the CD38-binding fusion protein comprises an anti-CD38 antibody fused to an attenuated interferon alpha-2b.

A CD38-binding fusion protein for use in a method of treating melanoma, the method comprising administering to a subject in need thereof 60-120 mg of the CD38-binding fusion protein once every three weeks, wherein the CD38-binding fusion protein comprises an anti-CD38 antibody fused to an attenuated interferon alpha-2b.

A method of treating multiple myeloma, the method comprising administering to a subject in need thereof a composition comprising a CD38-binding fusion protein, wherein the CD38-binding fusion protein comprises an anti-CD38 antibody fused to an attenuated interferon alpha-2b, wherein the CD38-binding fusion protein is administered at 1.5-6.0 mg/kg of the subject or wherein 120-240 mg of the CD38-binding fusion protein is administered to the subject.